Abstract:Purpose: Trop2, a cell membrane glycoprotein, is overexpressed in almost all epithelial cancers. This study aimed to explore the mutational characteristics and significance of Trop2 in breast cancer (BC). Methods: Patients diagnosed with BC (n = 77) were enrolled to investigate expression level and clinical characteristics of Trop2. Database of cBioPortal and Kaplan-Meier Plotter were used to evaluate the effects of Trop2 (TACSTD2) genomic ateration and mRNA expression levels on disease-free survival (DFS) and relapse-free survival (RFS), respectively. Based on next generation sequencing analysis, the Trop2 mutation characteristics of BC patients were deeply depicted. In addition, Trop2 expression, mutation and methylation signature associated with Trop2 mutations were analyzed. Results: Trop2 mutation and high expression of Trop2 were predictive biomarker for shorter DFS and RFS in BC. The positive rate of Trop2 expression in these 77 BC patients was 96.1% (74/77). Based on the Trop2 expression level, the patients were classified into Trop2 negative group, medium expression group and high expression group. The mutation frequencies of MAP3K1, NOTCH2, PTEN and MAGI2 were significantly higher in Trop2 medium expression group than high expression group. Moreover, we investigated the effect of the Trop2 mutations on other genes, including co-expressed genes, differentially mutated genes, differentially expressed genes, gene methylation and phosphorylation. We found that MED8, DPH2, KDM4A, EBNA1BP2, USP1, IPO13, CGAS, PRKAA2, NCOA7, ASCC3 and ABRACL were differentially expressed, mutated and methylated between Trop2 mutation group and wild group. Conclusion: MAP3K1, NOTCH2, PTEN and MAGI2 mutations were significantly different between Trop2 medium expression and Trop2 high expression BC patients. The effects of Trop2 mutation on the expression, variation, methylation, and phosphorylation of other genes were comprehensively revealed. High expression level of Trop2 and Trop2 mutation were predictive biomarker for poor prognosis and targeted therapy in BC.

The clinical research of Trop2 as a potentially therapeutic target in oral tongue squamous cell carcinoma

Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type

Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma.

Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation

Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma

Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway.

Expression and significance of Trop-2 in non-small cell lung cancer

Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

Primary Study of Expression of TROP-2 in Human Pulmonary Adenocarcinoma and Cell Lines

TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis

Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy

The Role of TROP-2 in the Progression and Target Therapy in Penile Squamous Cell Carcinoma.

Trop-2 expression and the tumor immune microenvironment in cervical cancer

Trop2 inhibition of P16 expression and the cell cycle promotes intracellular calcium release in OSCC

TROP 2 is associated with the recurrence of patients with non-muscle invasive bladder cancer

Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation

Expression and clinical significance of TRB3 and p-AKT in oral tongue squamous cell carcinoma

Overexpression Of Trophoblast Cell Surface Antigen 2 As An Independent Marker For A Poor Prognosis And As A Potential Therapeutic Target In Epithelial Ovarian Carcinoma

High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

Targeting Trop-2 in Cancer: Recent Research Progress and Clinical Application